Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY25 results · Apr–Jun 2024
Natco Pharma reported revenue from operations of ₹1,362.60 crore (up 19.5% from Q1 FY24) and net profit of ₹668.50 crore (up 59.1% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,362.60 | 1,140.50 | +19.5% | 1,068.30 | +27.5% |
| Other income | 48.10 | 19.70 | +144.2% | 42.00 | +14.5% |
| Total income | 1,410.70 | 1,160.20 | +21.6% | 1,110.30 | +27.1% |
| Profit before tax | 803.60 | 500.00 | +60.7% | 477.60 | +68.3% |
| Net profit for the period | 668.50 | 420.30 | +59.1% | 386.30 | +73.1% |
| EPS, basic (₹) | 37.32 | 23.26 | +60.4% | 21.56 | +73.1% |
| Net margin (%) | 49.1 | 36.9 | 36.2 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,236.90 | 1,048.30 | +18.0% | 964.80 | +28.2% |
| Other income | 39.80 | 14.60 | +172.6% | 35.90 | +10.9% |
| Total income | 1,276.70 | 1,062.90 | +20.1% | 1,000.70 | +27.6% |
| Profit before tax | 758.00 | 475.20 | +59.5% | 432.50 | +75.3% |
| Net profit for the period | 636.30 | 405.30 | +57.0% | 349.10 | +82.3% |
| EPS, basic (₹) | 35.53 | 22.43 | +58.4% | 19.49 | +82.3% |
| Net margin (%) | 51.4 | 38.7 | 36.2 |
Consolidated
- Filed with BSE
- 13 Aug 2024, 13:04 IST
- Board meeting
- 12 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2024, 13:04 IST
- Board meeting
- 12 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE